UBS downgraded Cytokinetics to Neutral from Buy with a price target of $92, up from $61. The firm’s previous bullish thesis on Phase 3 aficamten data has played out, and the stock trajectory is now likely contingent on M&A, which is difficult to predict, the analyst tells investors in a research note. UBS feels some level of M&A premium is already baked in and sees balanced risk/reward on consummation of M&A or “fizzling” of takeout possibility.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CYTK:
- Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
- Cytokinetics extends decline, down 26% after WSJ said Novartis back away
- Novartis backing away from pursuit of Cytokinetics, WSJ reports
- Cytokinetics sinks 23% after WSJ says Novartis backed away from takeover
- Notable open interest changes for January 10th
